alpha-MSH immunomodulation acts via rel/NF-kappa B in cutaneous and ocular melanocytes and in melanoma cells.
Haycock
J W
JW
University Division of Clinical Sciences, Northern General Hospital, Sheffield, United Kingdom. J.W.Haycock@Sheffield.ac.uk
Wagner
M
M
Morandini
R
R
Ghanem
G
G
Rennie
I G
IG
MacNeil
S
S
D000276:Adjuvants, Immunologic; D002460:Cell Line; D006801:Humans; D008544:Melanocytes / Q000187:drug effects / Q000378:metabolism*; D008545:Melanoma; D016328:NF-kappa B / Q000378:metabolism*; D020569:Proto-Oncogene Proteins c-rel / Q000378:metabolism*; D012878:Skin Neoplasms; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000494:pharmacology; D014602:Uvea / Q000166:cytology; D014604:Uveal Neoplasms; D000521:alpha-MSH / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D016328:NF-kappa B; D020569:Proto-Oncogene Proteins c-rel; D014409:Tumor Necrosis Factor-alpha; D000521:alpha-MSH